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Abstract
Previous studies have shown that transforming growth factor-L1 (TGF-L1) stimulates protein kinase C (PKC) via a
mechanism that is independent of phospholipase C or tyrosine kinase, but involves a pertussis toxin-sensitive G-protein.
Maximal activation occurs at 12 h and requires new gene expression. To understand the signaling pathways involved, resting
zone chondrocytes were incubated with TGF-L1 and PKC activity was inhibited with chelerythrine, staurosporine or H-7.
[35S]Sulfate incorporation was inhibited, indicating that PKC mediates the effects of TGF-L1 on matrix production.
However, there was little, if any, effect on TGF-L1-dependent increases in [3H]thymidine incorporation, and TGF-L1-
stimulated alkaline phosphatase was unaffected, indicating that these responses to the growth factor are not regulated via
PKC. TGF-L1 caused a dose-dependent increase in prostaglandin E2 (PGE2) production which was further increased by
PKC inhibition. The increase was regulated by TGF-L1-dependent effects on phospholipase A2 (PLA2). Activation of PLA2
inhibited TGF-L1 effects on PKC, and inhibition of PLA2 activated TGF-L1-dependent PKC. Exogenous arachidonic acid
also inhibited TGF-L1-dependent increases in PKC. The effects of TGF-L1 on PKC involve genomic mechanisms, but not
regulation of existing membrane-associated enzyme, since no direct effect of the growth factor on plasma membrane or
matrix vesicle PKC was observed. These results support the hypothesis that TGF-L1 modulates its effects on matrix
production through PKC, but its effects on alkaline phosphatase are mediated by production of PGE2 and protein kinase A
(PKA). Inhibition of PKA also decreases TGF-L1-dependent proliferation. We have previously shown that PGE2 stimulates
alkaline phosphatase through its EP2 receptor, whereas EP1 signaling causes a decrease in PKC. Thus, there is cross-talk
between the two pathways. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Transforming growth factor L-1 (TGF-L1) is an
important regulator of chondrocyte proliferation
and di¡erentiation that was originally puri¢ed from
demineralized bone based on its ability to stimulate
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the di¡erentiation of neonatal rat muscle cells into
chondrocytes [1^3]. TGF-L1 also regulates commit-
ted chondrocytes, particularly those in the endochon-
dral pathway [4,5]. Both alkaline phosphatase specif-
ic activity and proteoglycan production [5,6] are
increased by this growth factor. In addition to its
direct e¡ects on cells, TGF-L1 works in conjunction
with other cytokines to modulate their e¡ects, further
amplifying its potential biological functions [7].
Cells in the resting zone of costochondral growth
plate cartilage are particularly sensitive to TGF-L1
[5,8,9]. These cells exhibit maximal responses to
doses of 0.22 ng/ml, whereas higher concentrations
are required for osteoblasts to exhibit the same e¡ect
[10,11]. TGF-L1 regulates proliferation of resting
zone chondrocytes in a time-dependent manner,
causing increased proliferation following a 24 h ex-
posure, but decreased proliferation following longer
exposure [5]. Alkaline phosphatase is stimulated in a
biphasic manner [5], indicating increased di¡erentia-
tion. Indeed, exposure of resting zone chondrocytes
to TGF-L1 for more than 96 h causes the cells to
assume a hypertrophic chondrocyte phenotype [12].
The e¡ects of TGF-L1 are synergistic with those of
24,25-(OH)2D3, further supporting the role of this
growth factor in regulating the di¡erentiation and
endochondral maturation of these cells [13].
Resting zone chondrocytes synthesize TGF-L1 in
latent form [4,14] and store it in their extracellular
matrix as a 290 kDa complex consisting of latent
TGF-L1, latent TGF-L1 binding protein-1 and the
latency-associated peptide [15]. Extracellular matrix
vesicles produced by these cells can activate latent
TGF-L1 when they are exposed to 1,25-(OH)2D3
[14]. The interrelationship of TGF-L1 action and vi-
tamin D metabolites is also demonstrated by the fact
that TGF-L1 causes resting zone cells to produce
increased 1,25-(OH)2D3 within 1 h and increased
24,25-(OH)2D3 at 24 h [16], which is correlated
with TGF-L1-dependent downregulation of the 1K-
hydroxylase and upregulation of the 24-hydroxylase
in these cells [9].
TGF-L1 causes increased protein kinase C (PKC)
activity in resting zone cells [8,17], suggesting that
PKC may be involved in mediating its actions on
these cells. To determine if this was the case, we
treated the cells with TGF-L1 and examined the ef-
fects of PKC inhibition on [3H]thymidine incorpora-
tion, alkaline phosphatase speci¢c activity and pro-
teoglycan sulfation. Since prostaglandin E2 (PGE2) is
also known to modulate PKC activity in these cells
[18], we also examined if TGF-L1 exerts its e¡ects
through prostaglandin production. The role of pro-
tein kinase A (PKA) was examined as a function of
cell proliferation. We then examined the mechanisms
by which TGF-L1 stimulates PKC, focusing on the
role of phospholipase A2 (PLA2) and the product of
its action, arachidonic acid. Finally, we determined if
TGF-L1 exerts a direct action on membrane PKC.
2. Materials and methods
2.1. Reagents
The following chemicals were purchased from Sig-
ma Chemical (St. Louis, MO, USA): palmitic acid,
indomethacin (a general cyclooxygenase inhibitor),
quinacrine (PLA2 inhibitor) and reagents for the al-
kaline phosphatase assay. The following chemicals
were purchased from Calbiochem (San Diego, CA,
USA): 1,2-dioctanoyl-sn-glycerol (DOG), cheleryth-
rine (PKC inhibitor), staurosporine, H-7, H-8, arachi-
donic acid and U73122 (phospholipase C inhibitor).
The following chemicals were purchased from BIO-
MOL Research Laboratories (Plymouth Meeting,
PA, USA): selective PLA2 inhibitors oleyloxyethyl-
phosphorylcholine (OEPC) and arachidonyltri£uoro-
methyl-ketone (AACOCF3), and selective PLA2 ac-
tivators mastoparan and melittin. PKC assay
reagents and Dulbecco’s modi¢ed Eagle medium
(DMEM) were obtained from Gibco BRL (Gaithers-
burg, MD, USA). The protein content of each sam-
ple was determined using the bicinchoninic acid
(BCA) protein assay reagent [19] obtained from
Pierce Chemical (Rockford, IL, USA). Recombinant
human TGF-L1 was obtained from RpD Systems
(Minneapolis, MN, USA). Fetal bovine serum
(FBS) was purchased from Atlanta Biologicals (Nor-
cross, GA, USA). The PGE2 radioimmunoassay kit,
[3H]thymidine, [35S]sulfate and [32P]ATP were ob-
tained from NEN DuPont (Boston, MA, USA).
2.2. Chondrocyte cultures
The rat costochondral chondrocyte culture system
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used in this study has been described in detail pre-
viously [20]. Cells were derived from the resting zone
and growth zone of costochondral cartilage from 125
g male Sprague-Dawley rats (Harlan, Indianapolis,
IN, USA) and cultured in DMEM containing 10%
FBS, 50 Wg/ml vitamin C and antibiotics in an at-
mosphere of 5% CO2 and 100% humidity at 37‡C.
Fourth passage cells were used for all experiments
since prior studies have shown that these cells retain
their chondrogenic phenotype, including synthesis of
type II collagen [21], ability to form cartilage nodules
when implanted into nude mouse thigh muscle [22],
and di¡erential responsiveness to vitamin D metab-
olites and a number of other factors [5,14,20,21,23^
28].
When the cells reached con£uence, they were
treated with TGF-L1 for 24 h to assess physiological
responses and for 12 h to measure PKC speci¢c ac-
tivity. Recombinant human TGF-L1 was dissolved in
phosphate-bu¡ered saline and diluted to the appro-
priate concentration with DMEM before addition to
the cultures. Control cultures contained vehicle or
inhibitors or activators.
2.3. Role of PKC in physiologic response of resting
zone cells to TGF-L1
To determine whether the response of resting zone
cells to TGF-L1 involves PKC, con£uent fourth pas-
sage cultures were incubated with TGF-L1 þ PKC
inhibitors as described below. We used chelerythrine
as an inhibitor of PKC for these studies because of
its relative speci¢city for the enzyme. Chelerythrine
has an IC50 of 0.05 WM for PKC, whereas its IC50 for
PKA is s 50 WM [29]. H-7, H-8 and staurosporine
also inhibit a casein kinase and a myosin light chain
kinase [30]. Staurosporine has also been reported to
inhibit certain tyrosine kinases as well [31]. PKC in-
hibitor peptide 19-36, which is speci¢c for PKC,
could not be used for these studies because it is too
big to penetrate the cell membrane [32]. We used
staurosporine to con¢rm our observations with chel-
erythrine, since staurosporine is an e¡ective inhibitor
of most isoforms of PKC, albeit not as speci¢c as
chelerythrine. In addition, cultures were treated with
H-7 [33].
2.3.1. [3H]Thymidine incorporation
DNA synthesis was assessed by measuring
[3H]thymidine incorporation into trichloroacetic
acid (TCA) insoluble cell precipitates as described
previously [21]. Quiescence was induced by incubat-
ing con£uent cultures for 48 h in DMEM containing
1% FBS. The medium was then replaced for 24 h
with DMEM containing 1% FBS, vehicle þ TGF-L1
and the appropriate concentration of PKC inhibitor.
PKC activity in cultures treated with 0.22 ng/ml
TGF-L1 was inhibited with either 0.01 or 0.10 WM
chelerythrine [29], or 1 or 5 WM staurosporine [34]
for 24 h. In addition, cultures were treated with 0.88
ng/ml TGF-L1 þ PKC inhibitor H-7 (1, 5 or 10 WM)
[33]. Two hours prior to harvest, [3H]thymidine was
added. Radioactivity in TCA-precipitable material
was measured by liquid scintillation spectroscopy.
2.3.2. Alkaline phosphatase activity
Alkaline phosphatase (orthophosphoric monoester
phosphohydrolase, alkaline (EC 3.1.3.1)) was mea-
sured as a function of release of para-nitrophenol
from para-nitrophenylphosphate at pH 10.2 [35]. En-
zyme activity was assayed in lysates of the cell layer,
as well as in isolated matrix vesicle and plasma mem-
branes as previously described [36]. Cultures were
treated with 0.11, 0.22 or 0.88 ng/ml TGF-L1 þ 1 or
10 WM chelerythrine.
2.3.3. [35S]Sulfate incorporation
Proteoglycan synthesis was assessed by measuring
[35S]sulfate incorporation by con£uent cultures of
fourth passage resting zone chondrocytes using a
modi¢cation of the method of O’Keefe et al. [37].
In prior studies, we found that the amount of radio-
labeled proteoglycan secreted by the chondrocytes
into the medium was less than 15% of the total ra-
diolabeled proteoglycan (medium and cell layer) syn-
thesized [38,39]. Because of this, we only examined
the e¡ects of hormone and growth factor treatment
on [35S]sulfate incorporation in the cell layer. At con-
£uence, fresh medium containing vehicle þ 0.11, 0.22
or 0.88 WM TGF-L1 þ 1 or 10 WM chelerythrine was
added to the cells and the incubation continued for
an additional 24 h. Four hours prior to harvest, 50 Wl
DMEM containing 18 WCi/ml [35S]sulfate and 0.814
mM carrier sulfate was added to each culture. At
harvest, the conditioned media were removed, the
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cell layers (cells and matrix) collected and the
amount of [35S]sulfate incorporated determined by
liquid scintillation spectrometry. The protein content
was determined using the BCA protein assay and the
data expressed as disintegrations per minute per mg
protein in the cell layer.
2.3.4. PGE2 production
PGE2 production by resting zone chondrocyte cul-
tures treated with TGF-L1 was assessed by radioim-
munoassay. Cultures were treated for 24 h with 0.11
or 0.22 ng/ml TGF-L1 in the presence or absence of
0.01, 0.1 or 1 WM chelerythrine or H-7 and then
assayed for PGE2 production using a radioimmuno-
assay kit (NEN DuPont, Boston, MA, USA).
2.4. Role of PKA
To assess the role of PKA in cell response to TGF-
L1, the resting zone chondrocytes were incubated
with 0.88 ng/ml TGF-L1 þ 1, 5 or 10 WM H-8 [33].
[3H]Thymidine incorporation was measured as de-
scribed above.
2.5. Role of PLA2 in TGF-L1-dependent regulation of
PKC
2.5.1. PKC speci¢c activity
Cell layer lysates containing equivalent amounts of
protein were mixed for 20 min with a lipid prep-
aration containing phorbol-12-myristate-13-acetate,
phosphatidylserine and Triton X-100 mixed micelles
to provide the necessary cofactors and conditions for
optimal enzyme activity [40]. To this mixture, a high-
a⁄nity myelin basic protein peptide and [32P]ATP
(25 W Ci/ml) were added to a ¢nal assay volume of
50 Wl. Following a 10 min incubation in a 30‡C
waterbath, samples were spotted onto phosphocellu-
lose discs, which were then washed twice with 1%
phosphoric acid and once with distilled water to re-
move unincorporated label prior to placement in a
scintillation counter.
2.5.2. PLA2 activation
We examined the role of PLA2 in TGF-L1-depen-
dent activation of PKC by selectively activating or
inhibiting the enzyme. To examine the e¡ect of PLA2
activation on PKC activity in control and TGF-L1-
treated cultures, the PLA2 activators mastoparan
(wasp venom peptide) [41] and melittin (bee venom
peptide) [42] were used. Cultures were treated for 12
h with vehicle alone; 0.22 ng/ml TGF-L1; 0.4, 2 or
20 Wg/ml mastoparan; or 0.22 ng/ml TGF-L1+0.4,
2 or 20 Wg/ml mastoparan. Melittin was used in
a similar fashion, except the concentrations were
0.03, 0.3 and 3 Wg/ml.
2.5.3. PLA2 inhibition
Quinacrine was used as a general inhibitor of
PLA2 activity [43]. Cultures were treated for 12 h
with DMEM containing 10% FBS plus 0.22 ng/ml
TGF-L1 þ 0, 0.1, 1.0 or 10 WM quinacrine as de-
scribed previously [18]. Since quinacrine is a general
inhibitor of PLA2, we also examined the e¡ects of
0.1, 1 and 10 WM OEPC, which selectively inhibits
secretory PLA2 [44], and 0.1, 1 and 10 WM AA-
COCF3, which is speci¢c for cytosolic forms [45].
In each instance, cultures were treated with 0.22
ng/ml TGF-L1+inhibitor for 12 h. Control cultures
were treated with TGF-L1+the inhibitor vehicle
(0.02% ethanol in DMEM). PKC activity was mea-
sured at 12 h.
2.5.4. E¡ect of arachidonic acid
To assess the role of the PGE2 pathway in TGF-
L1-dependent PKC stimulation, we examined the ef-
fect of arachidonic acid, which is produced by PLA2,
the rate-limiting enzyme of prostaglandin produc-
tion. Cultures were treated for 12 h with vehicle
alone or with 0.11 or 0.22 ng/ml TGF-L1 in the pres-
ence or absence of 1, 10 or 100 WM arachidonic acid.
Control cultures were treated with TGF-L1+the ara-
chidonic acid vehicle (0.02% ethanol in DMEM).
PKC activity was measured as described above.
2.5.5. E¡ect of diacylglycerol and palmitic acid
To assess the role of other phospholipids in TGF-
L1 action, we examined the e¡ects of diacylglycerol,
which is the product of phospholipase C action, and
the e¡ects of the saturated fatty acid, palmitic acid,
on PKC activity. Cultures were treated with vehicle
alone, 0.11 ng/ml TGF-L1 or 0.22 ng/ml TGF-L1 in
the presence or absence of 1, 10 or 100 WM DOG or
palmitic acid. Control cultures were treated with
TGF-L1+vehicle (0.02% ethanol in DMEM). PKC
activity was measured at 12 h.
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2.5.6. Direct e¡ect of TGF-L1 on membrane-
associated PKC
To determine whether TGF-L1 regulates PKC ac-
tivity by direct action on membrane-associated en-
zyme, isolated plasma membranes and matrix
vesicles were incubated directly with TGF-L1. Both
membrane fractions have been shown previously to
contain PKCK and PKCj [46]; PKCK predominates
in plasma membranes, whereas PKCj predominates
in matrix vesicles. Because we previously demon-
strated that the e¡ect of TGF-L1 is on PKCK [8],
our assay conditions were speci¢cally designed to
detect this isoform.
For these experiments, plasma membranes were
isolated by di¡erential and sucrose density gradient
centrifugation of homogenized cells derived from
con£uent, fourth passage cells [36,47]. Matrix vesicles
were isolated by di¡erential centrifugation of the
trypsin-digested matrix [48]. Following assay for pro-
tein content [19], plasma membranes or matrix
vesicles were suspended in 0.9% NaCl and frozen
at 370‡C. Matrix vesicles isolated in this manner
typically exhibit greater than 2-fold enrichment of
alkaline phosphatase speci¢c activity when compared
with the plasma membranes [23,26,48] and have a
transmission electron microscopic appearance consis-
tent with matrix vesicles in vivo [48]. Matrix vesicles
or plasma membranes (1 mg protein/ml in 0.9%
NaCl containing 10% FBS) were incubated in the
absence (vehicle only) or presence of a ¢nal concen-
tration of 0.11, 0.22 or 0.88 ng/ml TGF-L1 for either
9, 90 or 270 min at 37‡C as described previously for
our vitamin D studies [46]. Following incubation,
samples were assayed for PKC activity.
2.6. Statistical analysis
Unless otherwise noted, the data presented below
are from one of three or more independent experi-
ments, all showing comparable results. Each data
point represents the mean þ S.E.M. for six cultures
(n = 6). For membrane PKC assays, each data point
is the mean þ S.E.M. for six membrane preparations,
where each preparation was derived from one T-150
£ask of cells. Data were analyzed by ANOVA. Stat-
istical signi¢cance was determined using Bonferroni’s
t-test, with P6 0.05 being considered signi¢cant.
Treatment/control ratios compare the means for
each variable from ¢ve or more independent experi-
ments as indicated in the ¢gure legend (nv 5). Stat-
istical comparisons were performed using the Wil-
coxon matched pair rank sum test. P6 0.05 was
considered signi¢cant.
3. Results
3.1. Role of PKC in cell response to TGF-L1
3.1.1. Cell proliferation
The results of this series of experiments showed
that cell proliferation involves a PKC-mediated path-
way, since all of the PKC inhibitors caused a dose-
dependent decrease in [3H]thymidine incorporation.
However, we were unable to demonstrate in an un-
equivocal manner that the TGF-L1-stimulated in-
crease in [3H]thymidine incorporation was also medi-
ated by a PKC-dependent pathway. This is because
much of the e¡ect of the PKC inhibitors could be
accounted for by the decrease in basal levels of DNA
synthesis. The PKC inhibitor chelerythrine signi¢-
cantly reduced [3H]thymidine incorporation in both
control and TGF-L1-treated cultures in a dose-
dependent manner (Fig. 1A). Treatment/control ra-
Table 1
The e¡ect of TGF-L1 and protein kinase inhibitors on
[3H]thymidine incorporation by resting zone chondrocytes
E¡ector DPM/well (U104)
Control 4.12 þ 0.04
PKC inhibitor (H-7)
1 WM 3.72 þ 0.11*
5 WM 3.10 þ 0.07*
10 WM 2.29 þ 0.20*
PKA inhibitor (H-8)
1 WM 3.90 þ 0.06*
5 WM 3.25 þ 0.07*
10 WM 2.01 þ 0.42*
TGF-L1 (0.88 ng/ml) 13.53 þ 0.34*
TGF-L1+1 WM H-7 12.09 þ 0.12*
TGF-L1+5 WM H-7 8.18 þ 0.11*#
TGF-L1+10 WM H-7 5.03 þ 0.31*#
TGF-L1+1 WM H-8 13.51 þ 0.40*
TGF-L1+5 WM H-8 12.08 þ 0.22*
TGF-L1+10 WM H-8 9.64 þ 0.46*#
Values represent the mean þ S.E.M. for six independent cul-
tures. *P6 0.05, treatment vs. control; #P6 0.05, TGF-L1+in-
hibitor vs. TGF-L1 alone; P6 0.05, vs. 1 WM inhibitor.
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tios from nine independent experiments demonstrate
that the PKC inhibitor consistently reduced
[3H]thymidine incorporation in control and TGF-
L1-stimulated cultures in a dose-dependent manner
(Fig. 1B). Similarly, another PKC inhibitor, stauro-
sporine, also blocked [3H]thymidine incorporation in
both control and TGF-L1-treated cultures (Fig. 2A).
The e¡ect was dose-dependent and was consistently
Fig. 2. The e¡ect of the PKC inhibitor staurosporine on TGF-
L1-induced [3H]thymidine incorporation by resting zone chon-
drocytes. Con£uent, fourth passage cells were treated with con-
trol media or 0.22 ng/ml TGF-L1 in the absence or presence of
1 or 5 WM staurosporine for 24 h. Two hours prior to harvest,
[3H]thymidine was added to the cultures. At harvest, the cell
layers were washed, precipitated with TCA as described in Sec-
tion 2 and counted in a scintillation counter. Data are from
one of nine independent experiments yielding similar results (A)
or combined and expressed as treatment/control ratios (B). For
the representative experiment shown, values are the mean þ
S.E.M. of six cultures. For treatment/control ratios, values are
the mean þ S.E.M. of nine experiments. *P6 0.05, vs. no stau-
rosporine; P6 0.05, 1 vs. 5 WM staurosporine; #P6 0.05, con-
trol vs. TGF-L1.
Fig. 1. The e¡ect of the PKC inhibitor chelerythrine on TGF-
L1-induced [3H]thymidine incorporation by resting zone chon-
drocytes. Con£uent, fourth passage cells were treated with con-
trol media or 0.22 ng/ml TGF-L1 in the absence or presence of
0.01 or 0.1 WM chelerythrine for 24 h. Two hours prior to har-
vest, [3H]thymidine was added to the cultures. At harvest, the
cell layers were washed, precipitated with TCA as described in
Section 2 and counted in a scintillation counter. Data are from
one of nine independent experiments yielding similar results (A)
or combined and expressed as treatment/control ratios (B). For
the representative experiment, values are the mean þ S.E.M. of
six cultures. For treatment/control ratios, values are the
mean þ S.E.M. of nine experiments. *P6 0.05, vs. no cheleryth-
rine; P6 0.05, 0.01 vs. 0.1 WM chelerythrine; #P6 0.05, con-
trol vs. TGF-L1.
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observed (Fig. 2B). In cultures treated with TGF-L1
and 5 WM staurosporine, [3H]thymidine incorpora-
tion was reduced to levels observed in unstimulated
cultures. Finally, the PKC inhibitor H-7 also caused
a dose-dependent decrease in [3H]thymidine incorpo-
ration in control cultures and in cultures treated with
0.88 ng/ml TGF-L1 (Table 1). At the highest concen-
tration of H-7, [3H]thymidine incorporation in the
TGF-L1-stimulated cultures was reduced to control
levels.
3.1.2. Alkaline phosphatase speci¢c activity
The TGF-L1-stimulated increase in alkaline phos-
Fig. 3. E¡ect of PKC inhibition on TGF-L1-induced proteogly-
can sulfation of resting zone chondrocyte cell layers. Cells were
treated for 24 h with varying concentrations of TGF-L1 in the
presence or absence of 1 or 10 WM chelerythrine and then as-
sayed for proteoglycan sulfation as described in Section 2. Each
data point is the mean þ S.E.M. for six cultures from one ex-
periment; the experiment was repeated two more times with
comparable results. *P6 0.05, vs. cultures not treated with
TGF-L1; P6 0.05, 1 WM vs. 10 WM chelerythrine; #P6 0.05,
chelerythrine vs. untreated control; P6 0.05, 0.88 ng/ml TGF-
L1 vs. 0.22 ng/ml TGF-L1.
Table 2
E¡ect of the PKC inhibitor, chelerythrine, on alkaline phosphatase speci¢c activity of resting zone chondrocytes
Treatment Alkaline phosphatase speci¢c activity (Wmol Pi/mg protein/min)
Control 1 WM chelerythrine 10 WM chelerythrine
Control 0.99 þ 0.11 0.75 þ 0.07# 0.59 þ 0.04#
0.11 ng/ml TGF-L1 1.42 þ 0.06* 1.57 þ 0.10* 1.61 þ 0.10*
0.22 ng/ml TGF-L1 1.62 þ 0.08* 1.64 þ 0.08* 1.59 þ 0.07*
0.88 ng/ml TGF-L1 1.00 þ 0.16 0.89 þ 0.13 0.80 þ 0.10
Values represent the mean þ S.E.M. for six independent cultures. *P6 0.05, vs. cultures not treated with TGF-L1; #P6 0.05, vs. not
treated with chelerythrine.
Fig. 4. E¡ect of PKC inhibition on TGF-L1-induced PGE2 pro-
duction by resting zone chondrocyte cell layers. Cells were
treated for 24 h with varying concentrations of TGF-L1 in the
presence or absence of 0.01, 0.1 or 1 WM chelerythrine (A) or
H-7 (B) and then assayed for PGE2 production as described in
Section 2. Each data point is the mean þ S.E.M. for six cultures
from one experiment; the experiment was repeated two more
times with comparable results. *P6 0.05, vs. cultures not
treated with chelerythrine or H-7; P6 0.05, 0.11 ng/ml TGF-
L1 vs. 0.22 ng/ml TGF-L1; #P6 0.05, vs. cultures not treated
with TGF-L1; P6 0.05, 0.1 WM H-7 vs. 1.0 WM H-7.
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phatase speci¢c activity is not regulated by a PKC-
dependent mechanism (Table 2). Even though inhi-
bition of PKC activity caused a dose-dependent de-
crease in basal enzyme activity, no e¡ect was noted
in the TGF-L1-treated cultures.
3.1.3. Proteoglycan production
TGF-L1 stimulates proteoglycan production by a
PKC-mediated pathway (Fig. 3). Inhibition of PKC
activity with chelerythrine had no e¡ect on proteo-
glycan sulfation in control cultures, but had a con-
centration-dependent inhibitory e¡ect in cultures
treated with TGF-L1. In cultures treated with 0.22
ng/ml TGF-L1, 1 WM chelerythrine reduced
[35S]sulfate incorporation by approximately 50%,
and 10 WM chelerythrine reduced proteoglycan sulfa-
tion to control levels. In cultures treated with 0.88
ng/ml TGF-L1, 10 WM chelerythrine blocked s 80%
of the TGF-L1-stimulated increase in [35S]sulfate in-
corporation.
3.1.4. PGE2 production
The production of PGE2 by resting zone chondro-
cyte cultures was increased by TGF-L1 in a dose-de-
pendent manner (Fig. 4). Inhibition of PKC with
either chelerythrine (A) or H-7 (B) caused a small,
dose-dependent increase in PGE2 production in the
control cultures. Chelerythrine, at 0.1 and 1.0 WM,
caused a small, dose-dependent increase in PGE2
production in cultures treated with TGF-L1. In cul-
tures treated with 1 WM chelerythrine, PGE2 produc-
tion in response to 0.11 ng/ml TGF-L1 was compa-
rable to that of cultures treated with 0.22 ng/ml. The
stimulatory e¡ect of H-7 was only seen in cultures
exposed to 1 WM inhibitor.
3.2. Inhibition of PKA with H-8
Modulation of cell proliferation under basal con-
ditions involves PKA, since inhibition of this signal-
ing pathway with H-8 caused a decrease in
[3H]thymidine incorporation (Table 1). H-8 also de-
Table 3
E¡ect of DOG or palmitic acid on TGF-L1-induced PKC activity of resting zone chondrocyte cell layers
Treatment PKC speci¢c activity (pmol PO4/Wg protein/min)
Control 0.11 ng/ml TGF-L1 0.22 ng/ml TGF-L1
Control 0.42 þ 0.02 0.90 þ 0.03# 1.54 þ 0.04#
1 WM DOG 0.46 þ 0.02 0.95 þ 0.04# 1.50 þ 0.08#
10 WM DOG 0.40 þ 0.02 0.93 þ 0.02# 1.53 þ 0.06#
100 WM DOG 0.58 þ 0.07 0.89 þ 0.04# 1.55 þ 0.06#
Control 0.56 þ 0.03 1.90 þ 0.10# 3.24 þ 0.17#
1 WM palmitic acid 0.59 þ 0.04 1.86 þ 0.11# 3.21 þ 0.14#
1 WM palmitic acid 0.60 þ 0.01 1.80 þ 0.10# 3.01 þ 0.09#
1 WM palmitic acid 0.61 þ 0.04 1.77 þ 0.10 3.07 þ 0.14#
Values represent the mean þ S.E.M. for six independent cultures. P6 0.05, 0.11 ng/ml TGF-L1 vs. 0.22 ng/ml TGF-L1; #P6 0.05, vs.
cultures not treated with TGF-L1.
Fig. 5. E¡ect of arachidonic acid on TGF-L1-induced PKC ac-
tivity of resting zone chondrocyte cell layers. Cells were treated
for 12 h with varying concentrations of TGF-L1 in the presence
or absence of 1, 10 or 100 WM arachidonic acid and then as-
sayed for PKC activity as described in Section 2. Each data
point is the mean þ S.E.M. for six cultures from one experi-
ment; the experiment was repeated two more times with com-
parable results. P6 0.05, 0.11 ng/ml TGF-L1 vs. 0.22 ng/ml
TGF-L1; *P6 0.05, vs. cultures not treated with arachidonic
acid; #P6 0.05, vs. cultures not treated with TGF-L1.
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creased the stimulatory e¡ect of TGF-L1 on
[3H]thymidine incorporation by 50%, implicating
PKA in the signaling pathway.
3.3. The role of arachidonic acid as mediator of
TGF-L1 action
As shown previously [49], arachidonic acid is a
negative regulator of PKC activity in resting zone
chondrocytes (Fig. 5). The results of the present
study indicate that the TGF-L1-dependent increase
in PKC may also be mediated by arachidonic acid.
In cultures treated with 0.11 ng/ml TGF-L1, 1 WM
arachidonic acid reduced PKC to levels below those
in unstimulated cultures, and at 10 and 100 WM, ar-
achidonic acid blocked the TGF-L1-dependent in-
crease in PKC. In cultures treated with 0.22 ng/ml
TGF-L1, arachidonic acid caused a dose-dependent
decrease in PKC. However, even at concentrations of
100 WM, only partial inhibition was achieved (55%).
DOG and palmitic acid had no signi¢cant e¡ect
upon basal PKC activity or upon the TGF-L1-depen-
dent increase in PKC activity (Table 3).
3.4. The role of PLA2 in the TGF-L1-dependent
regulation of PKC activity
Further evidence that arachidonic acid plays a role
in mediating the e¡ects of TGF-L1 is shown in Figs.
6 and 7. Stimulation of arachidonic acid release by
either mastoparan (Fig. 6A) or melittin (Fig. 6B) had
no e¡ect on basal PKC activity at 12 h, but caused
dose-dependent decreases in TGF-L1-stimulated cul-
tures.
Fig. 6. E¡ect of activating PLA2 on TGF-L1-induced PKC ac-
tivity of resting zone chondrocyte cell layers. Cells were treated
for 12 h with 0.22 ng/ml TGF-L1 in the presence or absence of
0.4, 2 or 20 Wg/ml mastoparan (A), or 0.03, 0.3 or 3 Wg/ml me-
littin (B) and then assayed for PKC activity as described in Sec-
tion 2. Each data point is the mean þ S.E.M. for six cultures
from one experiment; the experiment was repeated two more
times with comparable results. *P6 0.05, vs. cultures not
treated with PLA2 activator; #P6 0.05, vs. cultures not treated
with TGF-L1.
Fig. 7. E¡ect of inhibiting PLA2 on TGF-L1-induced PKC ac-
tivity of resting zone chondrocyte cell layers. Cells were treated
for 12 h with 0.22 ng/ml TGF-L1 in the presence or absence of
0.1, 1 or 10 WM quinacrine and then assayed for PKC activity
as described in Section 2. Each data point is the mean þ S.E.M.
for six cultures from one experiment; the experiment was re-
peated two more times with comparable results. *P6 0.05, vs.
cultures not treated with PLA2 inhibitor; #P6 0.05, vs. cultures
not treated with TGF-L1.
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Conversely, inhibition of PLA2 activity by quina-
crine increased PKC activity in both untreated and
TGF-L1-treated cultures at all concentrations tested
(Fig. 7). At 0.1 and 1 WM quinacrine, the e¡ect was
additive, but at 10 WM quinacrine, inhibition of
PLA2 was synergistic with the e¡ect of TGF-L1 on
PKC. OEPC, an inhibitor of secretory PLA2, in-
creased basal and TGF-L1-stimulated PKC activity
(Fig. 8A) to a greater extent than did AACOCF3, an
inhibitor of cytosolic PLA2 (Fig. 8B). At 10 WM, the
e¡ects of both OEPC and AACOCF3 were synergis-
tic with the e¡ects of TGF-L1.
3.5. Direct e¡ect of TGF-L1 on membrane PKC
The e¡ects of TGF-L1 on PKC are not mediated
by a direct e¡ect on pre-existing membrane-associ-
ated PKC (Table 4). There was no change in PKC
speci¢c activity of isolated matrix vesicles or plasma
membranes that were incubated directly with TGF-
L1. In addition, TGF-L1 did not elicit a series of
membrane-mediated events leading to an increase
in pre-existing membrane-associated PKC, since spe-
ci¢c activity did not change as a function of time.
4. Discussion
This study demonstrates that some, but not all, of
the e¡ects of TGF-L1 on resting zone chondrocytes
are mediated by PKC. Incorporation of [35S]sulfate
was blocked by PKC inhibitors, indicating that
TGF-L1-dependent proteoglycan production involves
a PKC signaling pathway. In contrast, inhibition of
PKC had no e¡ect on TGF-L1-stimulated alkaline
phosphatase speci¢c activity and little, if any, e¡ect
on [3H]thymidine incorporation, suggesting that
PKC is not involved. This is in contrast to 24,25-
(OH)2D3-dependent regulation of alkaline phospha-
tase and cell proliferation, in which inhibition of
PKC also inhibits the e¡ects of the vitamin D me-
tabolite (unpublished data).
Here, we show for the ¢rst time that production of
the local factor PGE2 is stimulated by TGF-L1.
Moreover, this stimulation is enhanced by inhibition
of PKC. This suggests that PKC is a negative regu-
lator of PGE2 production in resting zone chondro-
cytes [36]. Since release of arachidonic acid by PLA2
is the rate-limiting step in prostaglandin synthesis
[50], the observation that PKC inhibition enhances
PGE2 production suggests a feedback loop between
the PLA2 and PKC pathways. Recent studies sup-
port this hypothesis since changes in PLA2 activity
a¡ect PKC activity in these cells [51].
PGE2 has multiple e¡ects on the chondrocytes,
promoting di¡erentiation and anabolic responses
via cAMP production and PKC activity [52]. This
prostaglandin acts through its own membrane recep-
Fig. 8. E¡ect of inhibiting PLA2 on TGF-L1-induced PKC ac-
tivity of resting zone chondrocyte cell layers. Cells were treated
for 12 h with 0.22 ng/ml TGF-L1 in the presence or absence of
0.1, 1 or 10 WM OEPC (A), or 0.1, 1 or 10 WM AACOCF3 (B)
and then assayed for PKC activity as described in Section 2.
Each data point is the mean þ S.E.M. for six cultures from one
experiment; the experiment was repeated two more times with
comparable results. *P6 0.05, vs. cultures not treated with
PLA2 inhibitor; #P6 0.05, vs. cultures not treated with TGF-
L1.
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tors to exert its e¡ects on cells. Resting zone cells
have both EP1 and EP2 receptors, as well as an
EP1 variant, EP1v [53]. The increase in cAMP leads
to increased PKA activity. The importance of this
pathway in the response to TGF-L1 is evident in
the decrease in proliferation following treatment of
the cells with TGF-L1 and the PKA inhibitor, H-8.
Our results also con¢rm our previous observation
that TGF-L1 stimulation of PKC was dependent
on a pertussis toxin-sensitive G-protein [8]. Others
have also reported a role for a pertussis toxin-sensi-
tive G-protein-dependent pathway in the action of
TGF-L1 on renal tubular epithelial cells [54].
There is clearly cross-talk between the PGE2 and
PKC pathways, since inhibition of PGE2 production
increases PKC activity [18], inhibition of PKC in-
creases PGE2 production [55] and PGE2 inhibits
PKC activity [18]. The results of the present study
suggest that TGF-L1 may exert its e¡ects on PGE2
production in part via regulation of PLA2 and, there-
fore, on the amount of arachidonic acid. Inhibition
of PLA2 by the general inhibitor quinacrine, the se-
cretory PLA2 inhibitor OEPC, or the cytosolic PLA2
inhibitor AACOCF3, all enhanced the stimulatory
e¡ects of TGF-L1 on PKC. While this e¡ect was
additive with the increase in basal levels of PKC in
control cultures, at the highest concentration of
OEPC, which inhibits secretory PLA2, the e¡ects
were synergistic with TGF-L1, suggesting that the
secretory isozyme is responsible. In contrast, activa-
tion of PLA2 with either mastoparan or melittin de-
creased the e¡ects of TGF-L1 on PKC, but had no
e¡ect on basal enzyme activity. Finally, arachidonic
acid itself blocked the e¡ect of TGF-L1 on PKC at
concentrations of the fatty acid that had no e¡ect on
basal PKC activity. This e¡ect of arachidonic acid
was speci¢c since palmitic acid, a precursor of ara-
chidonic acid, had no e¡ect. Moreover, the diacylgly-
cerol, DOG, had no e¡ect, indicating that phospho-
lipase C and/or phospholipase D [56] were not
involved. This con¢rms our previous observation
that TGF-L1 stimulates PKC via a mechanism that
is independent of phospholipase C [8] based on inhi-
bition of enzymes with speci¢c inhibitors.
The results of this study help explain the synergis-
tic e¡ects of TGF-L1 and 24,25-(OH)2D3 on resting
zone chondrocytes. Both agents cause an increase in
PKC activity and PGE2 production [8,17,57], yet
they exert disparate e¡ects on the cell. Whereas
24,25-(OH)2D3 stimulates alkaline phosphatase ac-
tivity via PKC, TGF-L1 does not; whereas 24,25-
(OH)2D3 modulates proliferation via PKC, TGF-L1
does not. Thus, for these parameters at least, syner-
gistic responses may occur because more than one
mechanism is involved.
Time course of action may be another factor.
24,25-(OH)2D3 elicits rapid responses on existing
PKC associated with the plasma membrane and ma-
trix vesicles produced by the chondrocytes [46].
When plasma membranes are incubated directly
with 24,25-(OH)2D3, PKCK activity is increased. In
contrast, when matrix vesicles are incubated directly
with the vitamin D metabolite, PKCK activity is un-
a¡ected, but PKCj activity is decreased. TGF-L1
Table 4
Direct e¡ect of TGF-L1 on PKC activity of resting zone chondrocyte matrix vesicles and plasma membranes
Treatment PKC speci¢c activity (pmol PO4/Wg protein/min)
9 min 90 min 270 min
Matrix vesicles
Control 0.67 þ 0.08 0.74 þ 0.08 0.68 þ 0.05
0.11 ng/ml TGF-L1 0.60 þ 0.03 0.68 þ 0.04 0.67 þ 0.04
0.22 ng/ml TGF-L1 0.62 þ 0.12 0.72 þ 0.13 0.69 þ 0.04
0.88 ng/ml TGF-L1 0.64 þ 0.02 0.70 þ 0.02 0.70 þ 0.03
Plasma membranes
Control 0.24 þ 0.05 0.24 þ 0.01 0.32 þ 0.02
0.11 ng/ml TGF-L1 0.26 þ 0.02 0.22 þ 0.01 0.29 þ 0.01
0.22 ng/ml TGF-L1 0.24 þ 0.01 0.25 þ 0.01 0.33 þ 0.02
0.88 ng/ml TGF-L1 0.28 þ 0.03 0.26 þ 0.03 0.35 þ 0.02
Values represent the mean þ S.E.M. for six independent samples; each sample is the membranes isolated from one T-150 £ask of cells.
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does not exert a similar rapid e¡ect, however, since
there was no change in PKC activity of either the
plasma membranes or the matrix vesicles when they
were incubated directly with the growth factor.
Moreover, TGF-L1 does not elicit translocation of
PKC from the cytosol to the nucleus [8], whereas
24,25-(OH)2D3 does cause translocation to occur
[17].
Even for the genomic e¡ects on PKC, there are
di¡erences in the time course of action. Whereas
24,25-(OH)2D3 exerts its maximal e¡ects on PKC
at 90 min [17], maximal stimulation in response to
TGF-L1 is not observed until 12 h [8]. This implies
the existence of a cascade of regulatory events, ini-
tiated by 24,25-(OH)2D3, that enhance or comple-
ment the events initiated by TGF-L1. Neither
24,25-(OH)2D3 nor TGF-L1 require phospholipase
C, but 24,25-(OH)2D3 does exert its stimulatory ef-
fects via phospholipase D, resulting in diacylglycerol
production [18]. Diacylglycerol has no e¡ect on
the TGF-L1-dependent response, however. 24,25-
(OH)2D3 e¡ects require neither Gi nor Gs [18], but
TGF-L1-dependent PKC requires a pertussis toxin-
sensitive G-protein. Whereas 24,25-(OH)2D3 de-
creases PGE2 production and PKA is not required
for its action on resting zone chondrocytes, TGF-L1
causes an increase in PGE2 production and mediates
at least some of its e¡ects through PKA. For both
24,25-(OH)2D3 and TGF-L1, modulation of PLA2 is
pivotal. Inhibition of this enzyme activity by 24,25-
(OH)2D3 stimulates PKC, and this is true for TGF-
L1 as well. These observations suggest that the two
regulatory factors exert their e¡ects through separate
pathways and support the hypothesis that e¡ects of
24,25-(OH)2D3 on the cell may mediate the e¡ects of
TGF-L1.
Part of the biological signal of TGF-L1 is con-
veyed through Smad proteins [58,59]. Upon binding
to TGF-L1, the type II receptor associates with and
activates the type I receptor. The type I receptor
phosphorylates Smads 2 and 3, which translocate
into the nucleus and act as transcription factors
[60]. The actions of Smads in TGF-L1-dependent
gene expression are believed to be responsible for
part of the biological e¡ect of TGF-L1, albeit not
the entire e¡ect. Another important pathway known
Fig. 9. Mechanisms of TGF-L1 action in resting zone chondrocytes. TGF-L ; PLA2 ; arachidonic acid (AA); PGE2 ; alkaline phospha-
tase (ALPase); PKA; PKC; 3= inhibition, + = stimulation, ( þ ) = inhibition or stimulation was time-dependent.
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to be activated by TGF-L1 is the Ras^Raf^MEK^
MAPK pathway [61,62]. PKC impinges upon this
pathway as it has been recently demonstrated that
TGF-L1 activation of MAPK is dependent upon
PKC [63].
In summary, the results of this study con¢rm that
the physiological e¡ects of TGF-L1 on resting zone
chondrocytes are mediated by two separate path-
ways, the PKC pathway and the PGE2 pathway.
Additionally, there is cross-talk between these path-
ways (see Fig. 9). In this schematic diagram, we see
that TGF-L1 binds to its type II receptor, which
binds to the type I receptor. TGF-L1 type I receptor
activates Smad proteins and also activates a G-pro-
tein-dependent cascade, altering the activity of PLA2,
which produces arachidonic acid. Depending upon
the time it is measured, PLA2 activity may either
be activated or inhibited, as indicated by the ‘ þ ’.
Previously, we have reported that TGF-L1 inhibits
PLA2 in plasma membranes and matrix vesicles [5].
It is clear from the present study, however, that
TGF-L1 increases PGE2 production. This suggests
that TGF-L1-dependent PGE2 production is derived
from arachidonic acid released from phospholipids
other than phosphatidylethanolamine (PE) since
14C-labeled PE was used as a substrate for measuring
PLA2 activity.
Arachidonic acid is metabolized by cyclooxygenase
to PGE2, which binds to EP1 and EP2 PGE2 recep-
tors on the resting zone chondrocyte cell surface [53].
EP1 signaling inhibits PKC activity, while EP2 sig-
naling increases cAMP, which activates PKA. This is
consistent with our previous ¢nding that PGE2 treat-
ment inhibits PKC activity in resting zone chondro-
cytes [18], but stimulates alkaline phosphatase activ-
ity. This suggests that TGF-L1 signals through PKA
to alkaline phosphatase activity and through PKC to
stimulate proliferation and proteoglycan production.
Therefore, the regulation of both the PKC pathway
and the PGE2 pathway by TGF-L1 is essential for its
role in the proliferation and di¡erentiation of growth
plate chondrocytes.
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